.Morria Biopharmaceuticals.

Morria Biopharmaceuticals Plc Announces the Initiation of a Phase II Clinical Multi-dose Study of MRX-4 in Allergic Rhinitis
June 24,2008

LONDON (BUSINESS WIRE)
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has initiated a Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, multi-dose, double-blind, placebo-controlled study includes Rhinocort(R) as the steroid comparator arm. The study is expected to be completed by the end of Q3 2008.

"MRX-4 could provide unique, non-steroidal, first-choice drug treatment for allergic rhinitis."

The study is designed to evaluate the safety, tolerability, and efficacy of intranasal MRX-4 in AR patients outside of the local allergy season as compared with both placebo and an intranasal steroid. An experimental multi-functional anti-inflammatory drug (MFAID), MRX-4 is a non-steroidal potential treatment for AR that has generated promising pre-clinical efficacy data. In a Phase I equivalent trial completed in Israel earlier this year, it was shown to be well tolerated with no clinical significant adverse effects.

"We are excited about the opportunity to evaluate the safety and efficacy of MRX-4 in a multi-dose trial for treating allergic rhinitis," said Mark Cohen, chairman of the board of Morria. "MRX-4 could provide unique, non-steroidal, first-choice drug treatment for allergic rhinitis."

According to Dr. Yuval Cohen, Morria's president, it is rare for a first-in-man efficacy study in AR (phase II) to include a steroid comparator arm. "Most companies prefer waiting until they have generated substantial clinical efficacy data comparing their drug to a placebo before venturing to compare it to a standard market treatment, such as a nasal corticosteroid. Our decision to include the steroid comparator arm so early in our clinical development is a combination of our confidence in MRX-4's performance as well as the creativity of our clinical team in streamlining and maximizing the efficacy of our clinical development program. We believe that this will substantially increase the value of this data."

ABOUT ALLERGIC RHINITIS
Allergic rhinitis is a common condition that affects nearly 59 million people in the United States (nearly 20 percent of the population) with a market of close to $4 billion. Allergic rhinitis is characterized by inflammation of the nasal membranes accompanied by symptoms that may include sneezing, nasal congestion, nasal itching and rhinorrhea.

ABOUT MORRIA BIOPHARMACEUTICALS Plc
Morria Biopharmaceuticals Plc is a biopharmaceutical company focusing on the development of anti-inflammatory agents termed Multi-Functional Anti-Inflammatory Drugs (MFAID). Morria is determined to use its unique technological and cost advantage to become a major player in the $50bn anti-inflammatory drug market within the next decade through the introduction of novel drugs for the treatment of a variety of chronic inflammatory conditions including skin, airway and gastro-intestinal inflammatory diseases.

This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - Persons in the business of disseminating information.

SOURCE: Morria Biopharmaceuticals Plc
CONTACT: Yuval Cohen, Managing Director
53 Davies Street, London, W1K 5JH, United Kingdom
Tel: +44 (0)207 152 6341 or info@morria.com

Back to top

Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
June 11, 2008

LONDON (BUSINESS WIRE)
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has obtained regulatory approval from the South African Medicines Control Council (MCC) to initiate a Phase II study of MRX-4 in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, multi-dose, double-blind, placebo-controlled study includes a steroid comparator arm.

"We are excited to be taking this significant step toward testing a potentially safer, more effective, and more affordable treatment option for the significant commercial opportunity in the multi-billion dollar allergic rhinitis market".

The study will evaluate the safety, tolerability, and preliminary efficacy of intranasal MRX-4 in AR patients outside of allergy season as compared with both placebo and an intranasal steroid. An experimental multi-functional anti-inflammatory drug (MFAID), MRX-4 is a non-steroidal potential treatment for AR that was shown to be safe and well tolerated in a Phase I equivalent trial completed in Israel earlier this year.

"This study will provide valuable data regarding its potential in allergic rhinitis, including efficacy, tolerability and pharmacokinetic data," said Dr. Yuval Cohen, president of Morria. "We are excited to be taking this significant step toward testing a potentially safer, more effective, and more affordable treatment option for the significant commercial opportunity in the multi-billion dollar allergic rhinitis market".

SOURCE: Morria Biopharmaceuticals Plc
CONTACT: Yuval Cohen, Managing Director
53 Davies Street, London, W1K 5JH, United Kingdom
Tel: +44 (0)207 152 6341 or info@morria.com

Back to top

Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results from its Phase I Clinical Study of MRX-4 in Allergic Rhinitis patients
January 16, 2008

LONDON (BUSINESS WIRE)
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).

“We are entirely satisfied with these results” said Dr. Yuval Cohen, President of Morria. “They mark an important milestone in our clinical development plan which aims at offering a potentially safer and more effective treatment option in the multi-billion dollar AR market.”

MRX-4 was nasally administered as a single dose once a week for four consecutive weeks. The first administration was given without a nasal allergen challenge (NAC) while the subsequent three were carried out in conjunction with a NAC. The protocol was double-blinded and placebo-controlled.

During the trial, no adverse effects were observed with blood analysis and pharmacokinetic data further indicating safety.

“We are entirely satisfied with these results” said Dr. Yuval Cohen, President of Morria. “They mark an important milestone in our clinical development plan which aims at offering a potentially safer and more effective treatment option in the multi-billion dollar AR market.” Based on this data, Morria plans to initiate a large scale, statistically powered (n = 175) Phase II NAC clinical study in which patients will be treated for six days prior to allergen challenge. Such a study is common in AR clinical development. Further details regarding this study are expected shortly.

SOURCE: Morria Biopharmaceuticals Plc
CONTACT: Yuval Cohen, Managing Director
53 Davies Street, London, W1K 5JH, United Kingdom
Tel: +44 (0)207 152 6341 or info@morria.com

Back to top

Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
October 23, 2007

LONDON (BUSINESS WIRE)
Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced the initiation of a Phase I tolerance study of MRX-4 in 12 patients suffering from allergic rhinitis (AR).

“There is a real and urgent need for novel, non-steroidal treatments for inflammatory diseases such as allergic rhinitis. Morria’s drug platform could potentially offer such an alternative”

The randomized, placebo-controlled, double-blind clinical trial is the first of two modules focusing on safety for Morria’s first human study in AR. MRX-4 is nasally administered as a single dose either with or without an allergen challenge to determine tolerance. Results are expected by the end of Q4 2007.

“We are excited to be taking this significant step toward introducing a potentially safer, more effective, and more affordable treatment option to the multi billion-dollar AR market,” said Yuval Cohen (PhD), President of Morria.

Prof. Peter Barnes of the Department of Thoracic Medicine, National Heart & Lung Institute, Imperial College London and a consultant to Morria Biopharmaceuticals’ added: “There is a real and urgent need for novel, non-steroidal treatments for inflammatory diseases such as allergic rhinitis. Morria’s drug platform could potentially offer such an alternative”

SOURCE: Morria Biopharmaceuticals Plc
CONTACT: Yuval Cohen, Managing Director
53 Davies Street, London, W1K 5JH, United Kingdom
Tel: +44 (0)207 152 6341 or info@morria.com

Back to top

END OF PRESS RELEASE -->
Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
September 25, 2007

LONDON (BUSINESS WIRE)
Morria Biopharmaceuticals Plc, a private biopharmaceutical company focusing on first-in-class, novel non-steroidal anti-inflammatory drugs, today announced it has appointed Dr. Johnson Lau and Dr. David Sidransky to its board of directors.

"Their extensive pharmaceutical and corporate experience will provide valuable guidance in both our clinical development plan with our lead anti-inflammatory compounds and the development of the company from a corporate perspective."

Dr. David Sidransky (MD) is the director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine and is also a professor of oncology, otolaryngology-head and neck surgery, cellular and molecular medicine, urology, and genetics and pathology at the university. He is currently vice-chairman of the board of directors of ImClone Systems, lead independent chairman at Alfacell Inc. and serves on the board of directors of Zila Inc. and Xenomics. Dr. Sidransky is a founder of several private biotechnology companies and has served on numerous scientific advisory boards of both private and public companies, including Medimmune, Telik, Roche and Amgen. He was formerly on the board of scientific counselors at the National Institute of Dental and Craniofacial Research and is a member of the Recombinant DNA advisory committee at the National Institutes of Health. Dr. Sidransky sits on numerous editorial boards and has served as senior editor of several cancer-related journals. He is certified in internal medicine and medical oncology by the American Board of Medicine.

"We are excited to have Dr. Lau and Dr. Sidransky join Morria's board," said Mark Cohen, chairman of the board. "Their extensive pharmaceutical and corporate experience will provide valuable guidance in both our clinical development plan with our lead anti-inflammatory compounds and the development of the company from a corporate perspective."

SOURCE: Morria Biopharmaceuticals Plc
CONTACT: Yuval Cohen, Managing Director
53 Davies Street, London, W1K 5JH, United Kingdom
Tel: +44 (0)207 152 6341 or info@morria.com

Back to top

END OF PRESS RELEASE -->
Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
September 11, 2007

LONDON (BUSINESS WIRE)
Morria Biopharmaceuticals Plc, a private biopharmaceutical company focusing on first-in-class novel, non-steroidal anti-inflammatory drugs, announced that it has appointed Rosemary Mazanet M.D., Ph.D. as its interim Chief Executive Officer. Dr. Mazanet has substantial experience in the executive and operational management experience throughout thebiopharmaceutical industry.

"I am very excited to be involved with Morria and the development of their platform of therapeutic compounds addressing significant unmet medical needs in inflammation"

Dr. Mazanet serves on the Board of numerous private and public pharmaceutical companies. From June 1998 to February 2004, Dr. Mazanet served as Chief Scientific Officer and a General Partner of Oracle Partners, L.P., a healthcare investment firm. As Sr. Director of Clinical Research at Amgen in the early and mid 1990s, she was responsible for the submission of Corporate INDs, the registration strategy and conduct of Phase I, II and III clinical trials. Dr. Mazanet also serves as an independent director at GTx, Inc (Nasdaq: GTXI) and is a trustee at the University of Pennsylvania, School of Medicine where she received her M.D. and Ph.D. Dr. Mazanet was trained as an oncologist in the Harvard Medical System where she was also a faculty member.

"I am very excited to be involved with Morria and the development of their platform of therapeutic compounds addressing significant unmet medical needs in inflammation" said Dr. Mazanet. "This new family of Multifunctional Anti-Inflammatory Drugs (MFAIDS) could bring significant benefits to patients with many different inflammatory conditions including skin, respiratory and gastrointestinal indications."

Dr. Mazanet has a strong track record in operations, finance and regulatory affairs. We are very fortunate to have attracted the caliber of management as strong as Dr. Mazanet as Morria enters a new stage in its clinical development " said Mark Cohen, Chairman of the Board of Morria.

SOURCE: Morria Biopharmaceuticals Plc
CONTACT: Yuval Cohen, Managing Director
53 Davies Street, London, W1K 5JH, United Kingdom
Tel: +44 (0)207 152 6341 or info@morria.com

Back to top

Morria Biopharmaceuticals Plc announces the close of a private placement financing round in the amount of £1.6 million.
May 10th 2007

LONDON (BUSINESS WIRE)
Morria Biopharmaceuticals Plc (“Morria”), an anti-inflammatory drug development company, announced today that its has successfully completed a financing round raising £1.6 million through private placing of 2,000,000 Ordinary Shares at a price of £0.80 per share. The round was led by its Financial Consultants Charles Street Securities, Inc. (CSS) of London.

“The proceeds raised from our investors reflect the continuing confidence of the investment community in our ability to carryout our strategic vision and become a major innovative player in the anti-inflammatory industry”

The proceeds of the current financing will be used for advancing the development of Morria's lead drug candidates MRX4 and MRX6 including: i) pre-clinical development work for FDA IND filing for Phase IIa in contact dermatitis; ii) a Phase IIa trial in contact dermatitis; and iii) Phase IIa equivalent study in allergic rhinitis.

“The proceeds raised from our investors reflect the continuing confidence of the investment community in our ability to carryout our strategic vision and become a major innovative player in the anti-inflammatory industry” remarked Yuval Cohen, President of Morria.

Morria’s two leading drug candidates are MRX6, a topical formulation for treating contact dermatitis, and MRX4, an inhaled nasal spray for treating allergic rhinitis (AR). The MRX6 has already shown promising results in a proof of principle human study, while a proof of principle human study is expected to start with MRX4 for AR this summer.

SOURCE: Morria Biopharmaceuticals Plc
CONTACT: Yuval Cohen, Managing Director
53 Davies Street, London, W1K 5JH, United Kingdom
Tel: +44 (0)207 152 6341 or info@morria.com

Back to top

Morria Biopharmaceuticals Plc to present at the Acumen BioFin 4th Annual Global Healthcare Conference.
May 3rd 2007

LONDON (BUSINESS WIRE)
Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on first-in-class novel, non-steroidal anti-inflammatory drugs, announced today that Dr. Yuval Cohen, President of Morria, will deliver a presentation at the Acumen BioFin 4th Annual Global Healthcare Conference on Monday, May 14, 2007 at 8:00 a.m. local time at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

Dr. Cohen's presentation will provide an overview of the Company’s development of its leading drug candidates in the fields of allergic rhinitis and skin inflammation

Dr. Cohen's presentation will provide an overview of the Company’s development of its leading drug candidates in the fields of allergic rhinitis and skin inflammation, as well as its pre-clinical progress in inflammatory bowel disease and cystic fibrosis. Morria will also outline its latest key business developments including its discovery partnerships in eye-care and conjunctivitis areas.

SOURCE: Morria Biopharmaceuticals Plc
CONTACT: Yuval Cohen, Managing Director
53 Davies Street, London, W1K 5JH, United Kingdom
Tel: +44 (0)207 152 6341 or info@morria.com

Back to top

Morria Biopharmaceuticals Plc to present at the Atlas Venture Japan Biopharma Partnering Conference 2007 in Tokyo on March 20th.
March 13th 2007

LONDON (BUSINESS WIRE)
Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on first-in-class novel, non-steroidal anti-inflammatory drugs, announced today that Dr. Yuval Cohen, President of Morria, will deliver a presentation at the annual Atlas Venture Japan Biopharma Partnering Conference 2007, co-sponsored by Itochu Corp, NIF SMBC Ventures Co Ltd, Dechert LLP and EBD Group. The presentation will take place at 9:15am on Tuesday March 20th. The conference, by invitation only, will be held at the Park Hyatt Tokyo.

“This is our second invitation to Japan in the past six months”, stated Dr. Cohen. “We are very pleased with this opportunity and actively looking at partnering with Japanese market leaders to commercialize our novel products and forge R&D alliances”.

“This is our second invitation to Japan in the past six months”, stated Dr. Cohen. “We are very pleased with this opportunity and actively looking at partnering with Japanese market leaders to commercialize our novel products and forge R&D alliances”.

Dr. Cohen's presentation will provide an overview of the Company’s leading drug candidates in the fields of allergic rhinitis and skin inflammation as well as its pre-clinical progress in IBD and cystic fibrosis. Morria will also outline its latest key business developments including recently its discovery partnerships in eye care, conjuctivitis, and pharmaceutical compounds for drug eluting stents.

SOURCE: Morria Biopharmaceuticals Plc
CONTACT: Yuval Cohen, Managing Director
53 Davies Street, London, W1K 5JH, United Kingdom
Tel: +44 (0)207 152 6341 or info@morria.com

Back to top

Morria Biopharmaceuticals Plc. Announces publication of the results of its human Pilot Study in Contact Dermatitis Patients of MRX1, a novel first-in-class MFAID
February 14, 2007 06:00 AM Eastern Time

LONDON (BUSINESS WIRE)
Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today the publication of results from its human pilot clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX1. The results of the study are published in the upcoming edition of the International Journal of Immunopathology and Pharmacology. MRX1 was tested in a double-blind placebo controlled study on 11 contact dermatitis patients at the Hadassah University Hospital in Israel. The pilot clinical study findings show that a topical preparation of MRX1, applied twice daily for 14 days, scored 69% improvement based on conventional Physician's Assessment versus a standard 30% placebo effect generated by the moisturizing vehicle.

"These results mark an important milestone for Morria's unique proprietary technology", said Dr. Yuval Cohen, Managing Director of Morria Biopharmaceuticals Plc. "our aim is to continue expanding in the inflammatory skin disease area as well as accelerate our parallel program in the respiratory field and in gastro-intestinal inflammation. We expect more clinical trial in these fields to commence in the near future. These programs, coupled with the industry discovery partnerships we are currently engaged in, demonstrate the potent transformative potential that our technology possesses."

Prof. Arieh Ingber, Principle Investigator of the study and the head of the Department of Dermatology at Hadassah Hospital, added "I believe these results are very promising and may provide a much needed alternative to current topical treatments such as corticosteroids."

ABOUT CONTACT DERMATITIS
Contact dermatitis is an allergic condition in which patients develop skin reactions when coming into contact with certain materials/substances such as metals, latex and fabrics. The market for this condition is estimated at $600m. Contact dermatitis is a standard industry model of studying skin inflammation in humans.

SOURCE: Morria Biopharmaceuticals Plc
CONTACT: Yuval Cohen, Managing Director
53 Davies Street, London, W1K 5JH, United Kingdom
Tel: +44 (0)207 152 6341 or info@morria.com

Back to top

Morria Biopharmaceuticals Plc to present at the JAFCO Bio Conference 2006 in Tokyo on November 13th.
November 09, 2006 06:00 AM Eastern Time

LONDON (BUSINESS WIRE)
Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today that Yuval Cohen, Chief Executive Officer, will deliver a presentation at the annual JAFCO Bio Conference on Tuesday November 13th. The conference, by invitation only, will be held from November 12 - 13, 2006, at the Shinjuku Hilton Hotel in Tokyo.

"We view Japan as a unique and attractive market for our novel anti-inflammatory drug technology", stated Dr. Cohen. "Morria is looking at partnering with Japanese market leaders to commercialize our novel products and forge R&D alliances".

Dr. Cohen's presentation will provide an overview of the Company's leading drug candidates in the fields of allergic rhinitis and skin inflammation as well as its pre-clinical progress in IBD and cystic fibrosis. Morria will also outline its latest key business developments including recently launched joint ventures with several partners in ophthalmology and drug eluting stents.

SOURCE: Morria Biopharmaceuticals Plc
CONTACT: Yuval Cohen, Managing Director
53 Davies Street, London, W1K 5JH, United Kingdom
Tel: +44 (0)207 152 6341 or info@morria.com

Back to top

Morria Biopharmaceuticals Plc announces promising pre-clinical results in Inflammatory Bowel Disease (IBD)
LONDON 8 June 2006

Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today that its leading oral drug candidate, MRX-5, markedly ameliorated IBD symptoms in independently-conducted pre-clinical studies in animals.

The studies were conducted using the DSS mouse model, a standard industry model that mimics the effects of IBD. MRX-5 was given orally in several concentrations for up to 7 days of co-treatment with the disease-inducing stimulus. Morbidity was measured by weight loss, intestinal length and intestinal permeability. MRX-5 significantly improved all morbidity parameters and no adverse effects were noted in a parallel safety study.

"We are very pleased with this important milestone" said Dr. Yuval Cohen, Managing Director of Morria Biopharmaceuticals. "It demonstrates the tremendous broad-range potential of our leading drug candidates and follows on recent similar milestones in skin and lung inflammation. IBD is one of our three core indications and we plan to continue its pre-clinical development and prepare a regulatory submission for human studies".

ABOUT IBD
IBD is a chronic, incurable, life-long condition that features relapsing inflammation of the gastrointestinal tract and includes Crohn's disease and ulcerative colitis. Over 2 million patients are affected in the world's seven major pharmaceutical markets, spending in excess of $2bn a year on treatment. Current drugs are often associated with severe side-effects making them unsuitable for chronic treatment. MRX-5 is Morria's first in class oral lead drug candidate for IBD.

SOURCE: Morria Biopharmaceuticals Plc
CONTACT: Yuval Cohen, Managing Director
53 Davies Street, London, W1K 5JH, United Kingdom
Tel: +44 (0)207 152 6341 or info@morria.com

Back to top

See recent story in Feb 2006 issue of BioMed Journal
See story in Sept 2005 Issue of Bioventure View

Morria Biopharmaceuticals announces promising asthma pre-clinical results for treatment of asthma.
London date July 27 2005

Morria Biopharmaceuticals Plc., a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today that its leading inhaled drug candidate (termed MRX3) markedly ameliorated asthma symptoms and reduced the levels of several key inflammatory mediators in pre-clinical trials in animals. The results of these studies, conducted by Professor Saul Yedgar of the Hebrew University and his collaborators, appear in the current issue of Thorax.

In the study, rats with ovalbumin-induced asthma were pre-treated with inhaled MRX3 to test for the drug's efficacy as an asthma preventative therapy. MRX3 was compared to a placebo as well as a standard steroid (dexamethosone). The results show that MRX3 inhalation markedly ameliorated airway-constriction and airway inflammation and suppressed levels of the key inflammatory mediator associated with asthma: cysteinyl-leukotrienes, TNF-alpha and nitric oxide in lung macrophages. Furthermore, the drug had promising efficacy even when given after the asthma attack had already commenced, indicating a possible "reliever" function as well as a "preventer" function

"This looks like a promising new approach" said Professor Peter J. Barnes of Imperial College in London, an advisor to Morria its asthma development program.

"This is yet another promising indication of the considerable potential of our drug technology in treating chronic inflammatory diseases and replacing current therapies, particularly corticosteroids" said Dr. Yuval Cohen, Managing Director of Morria Biopharmaceuticals. "Our strategic goal is to initiate clinical trials in patients as soon as possible while continuing our synergistic efforts with our other leading products in the fields of dermatology and gastro-intestinal inflammation".

ABOUT MORRIA BIOPHARMACEUTICALS Plc
Morria Biopharmaceuticals Plc. is a biopharmaceutical company focusing on the development of anti-inflammatory agents termed Multi-Functional Anti-Inflammatory Drugs (MFAID). Morria is determined to use its unique technological and cost advantage to become a major player in the $50bn anti-inflammatory drug market within the next decade through the introduction of novel drugs for the treatment of a variety of chronic inflammatory conditions including skin, lung and gastro-intestinal inflammatory diseases.

SOURCE Morria Biopharmaceuticals Plc.
CONTACT: Yuval Cohen
UK contact information or info@morria.com

Back to top

Morria Biopharmaceuticals Plc Announces Completion of a Private Placement Financing Round-A in the Amount of £2.1m
London June 8 2005

Morria Biopharmaceuticals, Plc ("Morria"), a biopharmaceutical company focused on anti-inflammatory drug therapies, announced today the successfully completion of a £1.9 million private placing of 3,172,700 ordinary shares at a price of £0.60 per share. The round was led by its Financial Consultants Charles Street Securities (CSS) of London and follows a £200,000 private bridge financing.

"This first major round of funding reflects the confidence of the investment community in our ability to carry out our strategic vision and become a major innovative player in the anti-inflammatory industry", remarked Dr. Yuval Cohen, Managing Director. "We intend to use the proceeds of this funding in order to advance our three core pre-clinical development programs in the fields of dermatology, respiratory and gastro-intestinal inflammatory disorders. We believe that, if successful, our products could potentially replace steroids as the drug-of-choice for treating acute or chronic inflammation and revolutionize the way these diseases, affecting millions of people worldwide, are treated."

Morria has two leading drug candidates: MRX1, a topical formulation for treating atopic dermatitis and MRX3, an inhaled application for treating respiratory inflammation such as asthma and allergic rhinitis. Morria is planning to complete its pre-clinical safety studies and enter clinical phase testing. In addition, the company intends to advance its business strategy and research collaborations.

As a result of the completion of the Financing Round, Mr. Gilead Raday will be joining Morria's board on behalf of CSS.

ABOUT MORRIA BIOPHARMACEUTICALS Plc
Morria Biopharmaceuticals Plc. is a biopharmaceutical company focusing on anti-inflammatory drugs. Morria aims to become a major player in the $50 bn anti-inflammatory drug market within the next decade by developing novel drugs for the treatment of a variety of acute and chronic inflammatory conditions including skin, lung and gastro-intestinal inflammatory diseases. The company has an exclusive world-wide license from Yissum, the Research and Development company of the Hebrew University in Jerusalem.